BioStock: Aptahem's founder is back – now as Chairman of the Board

15 October 2020 - 17:13

On September 25, Bert Junno was elected Chairman of the Board of the biotech company Aptahem. As a founder of several companies in the industry, including Aptahem in 2014, Junno brings extensive experience from business development, drug development and fund raising in the resource-intensive industry. In order to finance the continued development towards clinical studies, Aptahem is currently raising just over 32 MSEK in a rights issue of units. BioStock reached out to Junno who shared his visions for the company. 

Read the full interview with Bert Junno at

This is a pressrelease from BioStock - Connecting Innovation & Capital

Provided by: Cision
Spotlight (Sweden)
Aptahem AB
Aptahem is active within biotechnology. The company conducts research and development of aptamer-based pharmaceuticals for the treatment of acute conditions caused by sepsis, blockage of blood vessels, stroke, and heart failure. Through early treatment, the pharmaceutical is intended to prevent damage to organs and tissue. A large part of the research is carried out in collaboration with partners...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date